Market Overview

Navidea Biopharmaceuticals Announces Results of the Annual Shareholder Meeting

Share:

Provides Update Related to the Upcoming FDA Meeting to Confirm the
Results of the Phase 2 Trial and Detail the Planned Phase 3 Trial for
Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or
"the Company"), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced
preliminary results of matters voted upon during the Company's 2018
annual general meeting of shareholders (the "AGM").

At the AGM, shareholders:

  • Re-elected Dr. Claudine Bruck to the Company's Board of Directors
  • Voted for an increase in the aggregate number of shares of common
    stock authorized for issuance under the Company's 2014 Stock Incentive
    Plan by 10,000,000 shares
  • Ratified Marcum LLP as Navidea's independent registered public
    accountant for 2018

The proposal to approve a potential amendment to the Company's amended
and restated certificate of incorporation to effect a reverse split of
the Company's common stock, as determined by the Board of Directors at
its discretion, of a ratio of not less than one-for-five and not more
than one-for-twenty, requires the affirmative vote of holders of a
majority of our Common Stock outstanding for approval. At the time of
the AGM, holders of a majority of Navidea's Common Stock voted were in
favor of the amendment, however not enough outstanding shares had been
voted to approve the proposal. As a result, the AGM was adjourned to
Monday, August 20, 2018 in order to give shareholders who had not yet
voted an opportunity to vote on the proposal.

Results are considered preliminary, with final figures reported on a
Form 8-K to be filed with the Securities and Exchange Commission.

At the AGM, the Company also provided details regarding its upcoming
meeting with the U.S. Food and Drug Administration ("FDA"). This meeting
represents the culmination of highly successful Phase 1 and Phase 2
clinical trials in the quantitative assessment of rheumatoid arthritis
("RA") disease. During this meeting, Navidea will discuss the Phase 2
trial results and present its proposed Phase 3 trial design for the
submission of a New Drug Application for an expansive diagnostic market
in RA. The tilmanocept diagnostic technology for RA also represents a
disruptive technology in diagnosing and treating the disease. This
approach to disease assessment is the first clinically objective
approach to quantitatively diagnosing RA. Following successful results
of the proposed Ph3 trial, the company would be eligible to submit these
findings to the FDA for approval of Navidea's first commercial product
since Lymphoseek.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization
efforts.

For more information, please visit www.navidea.com.

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, among other things: the timing
of, and our ability to, move forward with our business plans, including
as they relate to Macrophage Therapeutics, Inc., general economic and
business conditions, both nationally and in our markets; our history of
losses and uncertainty of future profitability; the final outcome of the
CRG litigation in Texas; our ability to successfully complete research
and further development of our drug candidates; the timing, cost and
uncertainty of obtaining regulatory approvals of our drug candidates;
our ability to successfully commercialize our drug candidates; our
expectations and estimates concerning future financial performance,
financing plans and the impact of competition; our ability to raise
capital sufficient to fund our development and commercialization
programs; our ability to implement our growth strategy; anticipated
trends in our business; advances in technologies; and other risk factors
set forth in this report and detailed in our most recent Annual Report
on Form 10-K and other SEC filings. You are urged to carefully review
and consider the disclosures found in our SEC filings, which are
available at www.sec.gov or
at http://ir.navidea.com.

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!